Serum Homocysteine could be used as abiomarker in Lupus Nephritis patients? | ||
| Al-Azhar International Medical Journal | ||
| Volume 2024, Issue 1, January 2024 | ||
| DOI: 10.58675/2682-339X.2251 | ||
| Authors | ||
| Mostafa A. AbdEllah1; Ashraf I. Mustafa1; Ahmed S. Ezz1; Amr A. Rezk2 | ||
| 1Rheumatology and Rehabilitation Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt | ||
| 2Clinical Pathology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt | ||
| Abstract | ||
| Background: SLE is a persistent inflammatory condition which impact around 50% of patients' kidneys. It is acknowledged that lupus nephritis (LN) is one among severest organ symptoms of SLE. New non-invasive laboratory assays are required to detect renal involvement without renal biopsy. Patients with LN are more susceptible to getting hyperhomocysteinemia. Therefore, homocysteine should be tested in all lupus nephritis patients since it is a modifiable marker. Aim of the work: to detect whether serum homocysteine can be used as abiomarker in Lupus Nephritis patients or not. Patients & methods: Thirty SLE patients participated in this study with biopsy proven (LN) attending to Bab El Sharia and Al Hussein University Hospitals in addition to fifteen healthy individuals. Results: According to the study, there is a statistically significant difference between active, non active patients and control group. Our results showed that (100.0%) of active patients had abnormal homomcysteine serum levels, (66.7%) of non active patients had abnormal homomcysteine serum levels. Conclusion: homocysteine is modifiable marker in SLE patients; elevated homocycteine levels are most likely to occur in lupus nephritis patients. | ||
|
Statistics Article View: 30 |
||
